Trefoil Therapeutics is a clinical-stage biotechnology company driven by the mission to restore sight to the millions of people who live with corneal diseases through the advancement of regenerative therapies. Founded and led by scientists with deep experience in the ophthalmology field, Trefoil is advancing an approach that leverages novel technology to treat a number of different corneal diseases. The company’s lead investigational medicine – TTHX1114 – has the potential to be first-in-class and is being studied for the treatment of corneal endothelial dystrophies and conditions via intracameral injection.
View Top Employees from Trefoil Therapeutics| Website | http://www.trefoiltherapeutics.com |
| Revenue | $5 million |
| Employees | 15 (15 on RocketReach) |
| Founded | 2013 |
| Address | 6330 Nancy Ridge Dr Suite 103, San Diego, California 92121, US |
| Phone | (917) 628-8502 |
| Technologies |
JavaScript,
PHP,
Google Analytics
+10 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Health Care, Biotechnology, Manufacturing, Therapeutics, Drug Discovery |
| Competitors | Boehringer Ingelheim Venture Fund, Prothix BV, Revitope, The Column Group |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies |
Looking for a particular Trefoil Therapeutics employee's phone or email?
Trefoil Therapeutics Questions
The Trefoil Therapeutics annual revenue was $5 million in 2024.
Mark Cpi is the Chief Medical Officer of Trefoil Therapeutics.
15 people are employed at Trefoil Therapeutics.
Trefoil Therapeutics is based in San Diego, California.
The NAICS codes for Trefoil Therapeutics are [541, 5417, 54].
The SIC codes for Trefoil Therapeutics are [283, 28, 80].
Top Trefoil Therapeutics Employees
-
22
-
35
-
View
Thomas Tremblay
Vice President, Clinical Development at Trefoil Therapeutics
San Francisco, CA, US31 -
35+
-
51
-
35
Related Companies
